RNS Number : 5087B MaxCyte, Inc. 14 February 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , February 14, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
RNS Number : 2329A MaxCyte, Inc. 01 February 2022 MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs Intima Bioscience to use
RNS Number : 3037Z MaxCyte, Inc. 24 January 2022 MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results · Fourth quarter 2021 revenue expected to be greater than $10 million · Full year 2021 revenue expected to be greater than $33.7
RNS Number : 9767W MaxCyte, Inc. 29 December 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 2758U MaxCyte, Inc. 01 December 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 December 2021 : MaxCyte (LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 2493T MaxCyte, Inc. 23 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Purchase of Common Stock - PDMR dealing Gaithersburg, Maryland , November 23, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused
RNS Number : 7413S MaxCyte, Inc. 17 November 2021 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights Gaithersburg, Maryland , November 17, 2021 - M axCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial
RNS Number : 0207S MaxCyte, Inc. 11 November 2021 MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD , November 11, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to
RNS Number : 2161R MaxCyte, Inc. 03 November 2021 MaxCyte Board Member Richard Douglas , PhD, Appointed Independent Chairman of the Board GAITHERSBURG, MD , Nov. 3, 2021 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on
RNS Number : 7940Q MaxCyte, Inc. 29 October 2021 Result of AGM GAITHERSBURG, MD , October 29, 2021 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research
